Europe’s healthcare M&A is poised to maintain strong momentum in 2026 following this year’s rebound in deal activity and renewed market confidence. “The sector is in a flywheel of productivity with drivers including ageing populations, workforce shortages, and technology adoption,” said Lloyd Price, Partner at Nelson Advisors. Following the turbulent tariff and regulatory environment at the start of 2025, the market is entering a period of relative confidence, he added.

In an investment banking landscape often dominated by career financiers and generalist institutions, Nelson Advisors has cultivated a distinct identity rooted in the operational experience of its leadership. The firm’s "Founders for Founders" philosophy is not merely a marketing tagline but a fundamental operational differentiator that dictates its approach to client selection, deal structuring and negotiation strategy.

The Specialist Boutiques: Firms like Nelson Advisors and Clipperton offer highly targeted, domain-specific expertise. They often cater to founder-led exits and specific verticals like Health IT, MedTech, and AI, providing a level of operational empathy and sector nuance that larger firms cannot provide.

European HealthTech this week is dominated by EU-level moves to unlock health data for AI, ongoing NHS digital transformation in the UK, and continued momentum around EU‑wide digital health initiatives and summits.​ European MedTech this week is defined by three themes: regulatory moves around data and devices, imaging and diagnostics innovation (largely via RSNA spillover), and fresh capital forming for growth-stage and infrastructure-heavy plays in Europe.​

Nelson Advisors Partner Lloyd Price has been invited to Judge the PitchFest Awards at ReWired 2026. This is the third time Lloyd has judged the prestigious awards, highlighting the pedigree of UK Digital Health and MedTech companies. Unlike standard "demo days," PitchFest is specifically designed to break down the barriers between start-ups and the NHS. The judges are not just venture capitalists but also Chief Information Officers (CIOs) and Chief Clinical Information Office

Nelson Advisors invited to Chair the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare' Panel at Health Tech Forward 2025 Nelson Advisors Partner Lloyd Price Chaired the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare panel' at Health Tech Forward 2025 in Barcelona this week. The  panel focused around 5 main questions debated by the guests Laura, Alberto and Naoufal. 1) Laura Busquet Raich, Head of Data Protection and ComplianceConsorci de Sa

Nelson Advisors Partner Lloyd Price was invited to Chair the discussions at the IESE Business School Healthcare Club event on the 3rd December in Barcelona. Lloyd was joined on the panel by Javier Matacàs, Investment Director at Careventures and ⁠Ilan Misano, CEO of X-Applied and former Head of the StartUp Growth Lab - Google Israel's startup accelerator.

The first week of December 2025 was defined by two major themes: the domination of RSNA 2025 by European imaging giants and a landmark public private investment partnership to fuel the continent's life sciences sector. The first week of December 2025 highlighted a pivotal shift in European HealthTech regulation, with the European Commission moving to unlock patient data for AI training, a long-awaited reform for the sector. In the UK, the NHS continued its digital integratio

Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives. Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care.

The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.

This report provides an exhaustive analysis of the leading boutique M&A investment bankers advising European Digital Health, HealthTech and MedTech founders. It challenges the traditional "league table" hierarchy, positing that for high-growth, innovation-led companies, specialized sector expertise and deep industrial connectivity often outweigh the balance sheet capabilities of global bulge bracket firms. The analysis distinguishes between the "Industrial MedTech" and "Digit

Join Future Health Intelligence for an end of year market insight webinar to review the key changes that have shaped 2025 and to gain insights into the key trends that will drive the NHS and UK health IT market in 2026 and beyond, identifying the key emerging market opportunities from the three left shifts set out in the NHS 10-year Plan: Fit for the Future.   

Updates for the week of November 24–28, 2025, are headlined by a major intervention from WHO Europe on AI safety, fresh capital for Nordic oncology innovation, and significant new regulatory guidance from the UK's MHRA. Updates from the week of November 24–28, 2025, highlight a significant shift in the regulatory landscape for European MedTech, alongside major investment news and post-conference analysis from MEDICA 2025.

In terms of volume and relevance to the mid-market founder, the demographic most prevalent in the European innovation ecosystem, firms like Rothschild & Co, Houlihan Lokey and highly specialised boutiques like Nelson Advisors, Arma Partners and Clipperton have emerged as the primary engines of liquidity.

Key developments in the European MedTech sector for the week of November 21st 2025, have been dominated by major regulatory shifts regarding AI, significant capital injections, and activity surrounding two major industry conferences. While the broader medical device sector is focused on hardware delays, the HealthTech conversation this week shifted sharply toward data access and AI liability.